Innately Adaptive or Truly Autoimmune: Is There Something Unique About Systemic Juvenile Idiopathic Arthritis?
Open Access
- 2 January 2020
- journal article
- review article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (2) , 210-219
Abstract
Systemic juvenile idiopathic arthritis (JIA) is a form of arthritis in childhood that is initially dominated by innate immunity–driven systemic inflammation and is thus considered a polygenic autoinflammatory disease. However, systemic JIA can progress toward an adaptive immunity–driven afebrile arthritis. Based on this observation of biphasic disease progression, a “window of opportunity” for optimal, individualized and target‐directed treatment has been proposed. This hypothesis requires testing, and in this review we summarize current evidence regarding molecular factors that may contribute to the progression from an initially predominantly autoinflammatory disease phenotype to autoimmune arthritis. We consider the involvement of innately adaptive γδ T cells and natural killer T cells that express γδ or αβ T cell receptors but cannot be classified as either purely innate or adaptive cells, versus classic B and T lymphocytes in this continuum. Finally, we discuss our understanding of how and why some primarily autoinflammatory conditions can progress toward autoimmune‐mediated disorders over the disease course while others do not and how this knowledge may be used to offer individualized treatment.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG FO 354/11‐1)
This publication has 94 references indexed in Scilit:
- Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritisRheumatology, 2012
- Alternative activation in systemic juvenile idiopathic arthritis monocytesClinical Immunology, 2012
- The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cellsProceedings of the National Academy of Sciences, 2011
- Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasisJournal of Experimental Medicine, 2011
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Annals of the Rheumatic Diseases, 2011
- Inflammasomes and autoimmunityTrends in Molecular Medicine, 2011
- Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity statesClinical Immunology, 2010
- A Mutation in the Nlrp3 Gene Causing Inflammasome Hyperactivation Potentiates Th17 Cell-Dominant Immune ResponsesImmunity, 2009
- Inflammasome-Mediated Disease Animal Models Reveal Roles for Innate but Not Adaptive ImmunityImmunity, 2009
- From interleukin‐23 to T‐helper 17 cells: human T‐helper cell differentiation revisitedImmunological Reviews, 2008